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Selective serotonin reuptake inhibitors (SSRIs) are used extensively in the treatment of
depression and anxiety disorders. The therapeutic beneﬁts of SSRIs typically require sev-
eral weeks of continuous treatment. Intriguingly, according to clinical reports, symptoms
of anxiety may actually increase during the early stages of treatment although more pro-
longed treatment alleviates affective symptoms. Consistent with earlier studies that have
used animal models to capture this paradoxical effect of SSRIs, we ﬁnd that rats exhibit
enhanced anxiety-like behavior on the elevated plus-maze 1 h after a single injection of the
SSRI ﬂuoxetine. Next we investigated the potential neural substrates underlying the acute
anxiogenic effects by analyzing the morphological and physiological impact of acute ﬂuox-
etine treatment on principal neurons of the basolateral amygdala (BLA), a brain area that
plays a pivotal role in fear and anxiety. Although earlier studies have shown that behavioral
or genetic perturbations that are anxiogenic for rodents also increase dendritic spine den-
sity in the BLA, we ﬁnd that a single injection of ﬂuoxetine does not cause spinogenesis
on proximal apical dendritic segments on BLA principal neurons an hour later. However,
at the same time point when a single dose of ﬂuoxetine caused enhanced anxiety, it also
enhanced action potential ﬁring in BLA neurons in ex vivo slices. Consistent with this ﬁnd-
ing, in vitro bath application of ﬂuoxetine caused higher spiking frequency and this increase
in excitability was correlated with an increase in the input resistance of these neurons.
Our results suggest that enhanced excitability of amygdala neurons may contribute to the
increase in anxiety-like behavior observed following acute ﬂuoxetine treatment.
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INTRODUCTION
Selective serotonin reuptake inhibitors (SSRIs) are used routinely
in the treatment of depression and a wide range of anxiety dis-
orders (Sheehan et al., 1993; van der Kolk et al., 1994; Stokes and
Holtz, 1997; Kent et al., 1998; Bezchlibnyk-Butler et al., 2000; Bon-
dareff et al., 2000; Stahl, 2000; Gorman, 2003). The therapeutic
beneﬁts of SSRI treatment in patients requires several weeks of
continuous treatment. Paradoxically,while such chronic treatment
regimens decrease symptoms of anxiety and depression, acute
effects of SSRI treatmentmay actually lead to an increase in anxiety
and an increased risk for suicidal ideation (Gorman et al., 1987;
Teicher et al., 1990; Mir and Taylor, 1997; Goldstein and Good-
nick, 1998; Masand and Gupta, 1999; Spigset, 1999; Fergusson
et al., 2005).
Unfortunately, little is known about the neural mechanisms
underlying this acute anxiogenic effect of SSRIs. The choice
of appropriate animal models poses a key challenge in gain-
ing mechanistic insights into this effect. Nevertheless, the acute
anxiogenic effect of SSRIs has been demonstrated in numerous
rodent models of anxiety-like behavior (Bodnoff et al., 1989;
Griebel et al., 1994; Sanchez and Meier, 1997; Dekeyne et al.,
2000; Kurt et al., 2000; Silva and Brandao, 2000; Bagdy et al.,
2001; Belzung et al., 2001; Koks et al., 2001; Salchner and Singe-
wald, 2002). Another promising lead comes from LeDoux and
colleagues who have shown that the same acute SSRI treatment
that increases anxiety-like behavior also enhances the acquisition
of fear memory in an auditory fear conditioning task (Burghardt
et al., 2004, 2007). Considerable evidence points to a crucial
role for the basolateral amygdala (BLA) in the acquisition and
expression of conditioned fear, and the underlying cellular and
molecular mechanisms have been studied extensively (McKernan
and ShinnickGallagher, 1997; Rogan et al., 1997; LeDoux, 2000;
Maren, 2000; Maren and Quirk, 2004). Therefore, ﬁndings on
the enhanced acquisition of auditory fear conditioning caused by
acute SSRI treatment provide a powerful framework for investi-
gating the cellular basis of this effect in the BLA. Results from
animal studies mentioned above gain further signiﬁcance in light
of neuroimaging studies that have revealed enhanced amygdala
activity in patients of affective disorders (Anand and Shekhar,
2003; Hasler et al., 2004; Hasler and Northoff, 2011). Further-
more, acute SSRI administration has been shown to enhance
amygdala activity in healthy humans (Del-Ben et al., 2005; McKie
et al., 2005). However, despite the pivotal role played by the
amygdala in fear, anxiety, and depression, little is known about
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how antidepressants such as SSRIs affect neurons in this brain
area.
In light of the accumulating evidence pointing to a potential
role for the BLA in the heightened fear and anxiety triggered by
acute SSRI treatment, the current study is aimed at examining
the cellular correlates of the anxiogenic effect of the SSRI ﬂu-
oxetine. To this end, we focus on two potential structural and
physiological mechanisms emerging from earlier studies. First,
behavioral or genetic manipulations that trigger the formation of
dendritic spines on excitatory principal neurons in the BLA also
enhance anxiety in rodents (Roozendaal et al., 2009). For instance,
both acute and chronic immobilization stress increase anxiety-like
behavior in the elevated plus-maze (EPM). Both of these stress
paradigms also increase the number of spines on BLA principal
neurons (Mitra et al., 2005). Further, BLA spinogenesis caused
by transgenic overexpression of brain-derived neurotrophic fac-
tor (BDNF) is accompanied by enhanced anxiety-like behavior
in mice (Govindarajan et al., 2006). Dendritic spines are highly
dynamic structures and stable changes in spine number have been
observed as early as an hour after behavioral training (Hofer and
Bonhoeffer, 2010). Thus, an increase in spine number in the BLA
may serve as a potential cellular substrate for the acute anxio-
genic effects of SSRIs. A second prediction comes from a number
of electrophysiological studies that have suggested a link between
enhanced fear and anxiety-like behavior and increased amygdala
activity. Behavioral stress that enhances fear learning also enhances
the excitability of BLA neurons (Manzanares et al., 2005). Bath
application of stress levels of the corticosterone enhanced the
excitability of BLA cells (Duvarci and Pare, 2007). Further, hyper-
excitability of the BLA can also be induced by intra-BLA infusion
of a corticotrophin releasing factor (CRF) receptor agonist, which
is normally released during stress (Rainnie et al., 2004). Thus,
anxiety induced by acute SSRI treatment may also be mediated
by an increase in neuronal excitability in the BLA. Therefore, in
the present study we test these two predictions by analyzing if the
acute anxiogenic effects of a single dose of the SSRI ﬂuoxetine is
accompanied by increases in the density of dendritic spines and
spiking activity in amygdalar principal neurons.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
MaleWistar rats (50- to 60- days old, 250–300 g) were used for all
experiments. All animals were housed in groups of two or three
with ad libitum access to food and water. They were maintained in
a temperature-controlled room, with a 14-h/10-h day/night cycle.
All procedures related to animal maintenance and experiments
were approved by the Institutional Animal Ethics Committee
(National Centre for Biological Sciences).
DRUGS
Fluoxetine Hydrochloride (courtesy of Hikal Ltd.) was dissolved
in 0.9% sterile saline and injected intraperitoneally (i.p.) at a dose
of 10mg/kg body weight. The 10mg/kg, i.p. dose of ﬂuoxetine
was used based on a number of previously published studies that
have already established the anxiogenic effect of this dose in vari-
ous tests for anxiety-like behavior and fear conditioning (Bodnoff
et al., 1989; Silva and Brandao, 2000; Bagdy et al., 2001; Burghardt
et al., 2007). The drug solution was made fresh daily and ani-
mals were weighed before each injection to ensure the accuracy of
drug dosage given. For the in vitro bath application of ﬂuoxetine
in brain slices, ﬂuoxetine was dissolved in artiﬁcial cerebrospinal
ﬂuid (aCSF) at a concentration of 50μM and the brain slices were
perfused with this solution (Karson et al., 1993; Mukherjee et al.,
1998).
ELEVATED PLUS-MAZE
The EPM, consisting of two opposite open arms (60 cm× 15 cm)
and two enclosed arms (60 cm× 15 cm, surrounded by a 15-cm
high opaque wall), was elevated 75 cm from the ground. The ani-
malswere tested on themaze 60min after an injection of ﬂuoxetine
or saline. Individual trials of 5min each were videotaped for sub-
sequent off-line analysis. At the beginning of each trial, animals
were placed at the center of the maze, facing an enclosed arm. All
trials were conducted between 10 a.m. and 2 p.m., and the maze
was cleaned with an ethanol solution after each trial.
MORPHOLOGICAL ANALYSIS
After testing for anxiety-like behavior on theEPM,all ratswere sac-
riﬁced under deep anesthesia. The brains were dissected out and
processed for Golgi staining (Shankaranarayana Rao and Raju,
2004; Govindarajan et al., 2006). Coronal sections (120μm thick)
were prepared and mounted on slides (Vyas et al., 2002). Slides
were coded before quantitative analysis, and the code was broken
only after the analysis was completed. Dendrites directly origi-
nating from cell soma were classiﬁed as main shafts, and those
originating from the main shafts were called primary dendrites.
Starting from the origin of the branch, and continuing away
from the cell soma, spines were counted along the ﬁrst 80μm
stretch of the primary dendrite. Spine density was analyzed using
the NeuroLucida image analysis system with the Olympus BX61
microscope. Spines were identiﬁed at a ﬁnal magniﬁcation of
1000× (10× eyepiece and 100× objective) in the microscope and
their position was marked on an 85μ/pixel image displayed on
the computer screen. All protrusions, irrespective of their mor-
phological characteristics, were counted as spines if they were in
direct continuity with the dendritic shaft. Finally, it may be noted
that our analysis, like all those involving Golgi staining, is likely
to lead to a systematic underestimation of spine density because
it is not possible to visualize spines pointing directly toward the
surface or extending beneath the dendrite (Feldman and Peters,
1979; Trommald et al., 1995; Trommald and Hulleberg, 1997).
In the present study, however, no attempt was made to correct
for these hidden spines, because of previously reported validation
(Horner and Arbuthnott, 1991) of the use of visible spine counts
for comparison between different experimental conditions.
IN VITRO SLICE ELECTROPHYSIOLOGY
Fluoxetine or saline injected rats were sacriﬁced under deep anes-
thesia. The brain was removed rapidly and 400μm thick coro-
nal brain slices containing the amygdala were prepared using a
Vibratome 1000 Plus (Vibratome, St. Louis,MO,USA). Slices were
transferred to a submerged chamber containing aCSF (126mM
NaCl, 2.5mM KCl, 26mM NaHCO3, 1.25mM NaH2PO4, 10mM
Glucose, 1mM MgCl2, and 2mM CaCl2) equilibrated with
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95%O2–5%CO2 at room temperature. Slices were incubated for at
least 1 h before being transferred to a superfused recording cham-
ber. Patch electrodes (3–6MΩ) were pulled from borosilicate glass
pipettes (O.D.: 1.5mm; I.D.: 0.86mm;Warner Instruments,Ham-
den,CT,USA) on a P-97 Flaming-BrownMicropipette Puller (Sut-
ter Instruments, Novato, CA, USA) and ﬁlled with a solution con-
taining 115mMK -gluconate, 20mMKCl,10mMHEPES,0.5mM
EGTA, 3mM MgATP, and 0.3mM NaGTP (pH 7.4, 290mOsm).
The internal solution was ﬁltered through a 0.2-μm ﬁlter before
use. Excitatory principal neurons in the lateral amygdala (LA)
were visually identiﬁed with infrared video-microscopy using an
upright microscope equipped with a 60X objective (Olympus
BX-50WI microscope, water immersion lens, 0.9NA). Data was
acquired with an HEKA EPC9 (HEKA Elektronik, Lambrecht,
Germany) ampliﬁer, ﬁltered at 2.9 kHz, and digitized at 20 kHz.
Whole-cell patch clamp recordings were performed at room tem-
perature in the current-clampmode (with themembranepotential
kept manually at −70mV). To obtain the frequency–current (f–
I ) relationship, action potential ﬁring in response to a series of
depolarizing current steps was recorded. The instantaneous ﬁring
rate for each current step was calculated from the inter-spike inter-
val. Saturating current intensities were excluded from the analysis.
Series resistance (Rs) was monitored throughout the experiment
by applying hyperpolarizing current steps. Only cells with a Rs
value less than 25MΩ that did not change bymore than 10%were
taken for analysis.
STATISTICS
All data values are expressed asmean± SEM.All statistical analyses
were performed using SPSS 9 and OriginPro 8. The behavior and
morphology data were analyzed using the Student’s t -test. For the
electrophysiology experiments, statistical analysis of the f/I curve
datawas done using a two-waymixed-modelANOVA (within sub-
ject factor – current injected, between subject factor – treatment)
when the experiment was done after in vivo ﬂuoxetine or saline
administration. Subsequent pairwise comparisons were made
using independent sample t -tests. For the in vitro ﬂuoxetine appli-
cation experiment, statistical analysis of the f/I curve data was
done using a two-way within subject ANOVA (within subject
factors – treatment and current injection). Subsequent pairwise
comparisons were made using paired t -tests. Statistical compar-
ison of ﬁring rates and input resistance before, during, and after
ﬂuoxetine application was done using paired t -tests.
RESULTS
ACUTE FLUOXETINE TREATMENT INCREASES ANXIETY-LIKE BEHAVIOR
IN THE ELEVATED PLUS-MAZE
In order to establish the anxiogenic effect of acute ﬂuoxetine
treatment (Griebel et al., 1994; Kurt et al., 2000; Silva and Bran-
dao, 2000; Koks et al., 2001), we ﬁrst examined how a single
injection of ﬂuoxetine (10mg/kg, i.p.) affected anxiety-like behav-
ior of male Wistar rats on the EPM 60min later (Figure 1A).
Fluoxetine-treated rats displayed elevated anxiety levels when
compared to saline injected controls as indicated by the signiﬁ-
cant reduction in open-arm time (Figure 1B; Saline: 58.9± 3.7,
N = 13; Fluoxetine: 35.0± 5.4, N = 12; p< 0.01) and open-
arm entries (Figure 1B; Saline: 63.5± 13.6, N = 13; Fluoxetine:
45.9± 13.2, N = 12; p< 0.01). The total number of entries into
both open and closed arms was not different between saline and
ﬂuoxetine-treated groups, suggesting that locomotor activity was
not affected. Thus, consistent with previous reports, we ﬁnd that
acute treatment with ﬂuoxetine increases anxiety-like behavior.
ACUTE FLUOXETINE TREATMENT DOES NOT AFFECT SPINE DENSITY
ON PRIMARY APICAL DENDRITES OF BLA PRINCIPAL NEURONS
Past studies have suggested a link between spinogenesis in the
BLA and an increase in anxiety-like behavior in the EPM (Mitra
et al., 2005; Govindarajan et al., 2006). These earlier studies
FIGURE 1 | Acute fluoxetine treatment increases anxiety-like behavior in
the elevated plus-maze. (A) Schematic representation of the experimental
protocol. MaleWistar rats were injected with ﬂuoxetine (10mg/kg, i.p.) or
saline and tested for anxiety-like behavior in the elevated plus-maze 60min
later. (B) Anxiety-like behavior was assessed by measuring the open-arm
exploration, i.e., the percentage of time spent in open-arm (left) and the
percentage of open-arm entries (middle). Fluoxetine injected rats spent less
time in the open-arm and made fewer entries to the open-arm when
compared to saline injected rats indicating high anxiety levels. The total
entries (right) were not different suggesting that there was no difference in
locomotor activity between the two groups. Saline: N =13, Fluoxetine:
N =12. Error bars represent SEM; *p<0.01.
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showed that manipulations, as diverse as acute stress or transgenic
up-regulation of BDNF, that increase anxiety-like behavior also
enhance spine density on the ﬁrst 80μm of primary apical den-
dritic segments on BLA principal neurons. Since acute ﬂuoxetine
treatment had the same anxiogenic effect, we hypothesized that it
could also have the same morphological effects on BLA principal
neurons. In order to test this prediction, a subset of the rats tested
for anxiety-like behavior were sacriﬁced immediately after behav-
ioral testing and the brains were processed for Golgi staining. The
density of dendritic spines was quantiﬁed on Golgi-impregnated
spiny principal neurons in the BLA (see Materials and Methods;
Figures 2A,B). We found no difference in the total number of
spines in the ﬁrst 80μm of the primary apical dendrites of BLA
neurons fromﬂuoxetine and saline treated animals (Figures 2C,D;
Saline: 115.4± 2.8, N = 5; Fluoxetine: 111± 3.7, N = 5). Further,
a more detailed segmental analysis in steps of 10μmdid not show
any effect of acute ﬂuoxetine treatment on spine density along any
segment of the dendrites analyzed (Figure 2E). These results show
that the acute anxiogenic effects of ﬂuoxetine are not accompanied
by an increase in spine density of the primary apical dendrites on
BLA principal neurons.
ACUTE IN VIVO TREATMENT WITH FLUOXETINE INCREASES
EXCITABILITY OF AMYGDALA NEURONS EX VIVO
Next we explored the possibility that the short-term effects
of ﬂuoxetine may be mediated by physiological rather than
structural changes in amygdalar neurons. An increase in amygdala
activity is often predictive of fear and anxiety-like behavior in
rodents (Maren and Quirk, 2004). Since acute ﬂuoxetine treat-
ment enhances these behavioral outputs of the amygdala (Figure 1;
Burghardt et al., 2004, 2007), we hypothesized that the same acute
in vivo administration of ﬂuoxetine may also enhance the ﬁring
output of principal neurons in the lateral amygdala (LA). To this
end, rats were subjected to a single injection of either ﬂuoxe-
tine (10mg/kg, i.p.) or saline and 60min later amygdala slices
were prepared from these injected animals (Figure 3A). Whole-
cell current-clamp recordings were carried out in LA principal
neurons, which exhibit spike frequency adaptation upon depo-
larizing current injections (Figure 3B). Action potential ﬁring
in response to somatic injections of increasing steps of depo-
larizing currents was recorded and the average instantaneous
ﬁring frequency was calculated for each current value. A com-
parison of these frequency–current (f–I) relationship plots for
LA neurons from saline and ﬂuoxetine-treated animals is pre-
sented in Figure 3C. Cells from ﬂuoxetine injected rats had sig-
niﬁcantly higher ﬁring rates compared to saline injected rats [F
(1, 23) = 4.41, p< 0.05]. There was also a signiﬁcant increase in
ﬁring rates with current injection [F (5, 115) = 409.94, p< 0.001].
However, the interaction between treatment and current injec-
tion was not signiﬁcant [F (5, 115) = 1.24]. Pairwise comparisons
also revealed that LA neurons from the ﬂuoxetine-treated rats
exhibited a signiﬁcant increase in spiking frequency (Figure 3C;
FIGURE 2 | Acute fluoxetine treatment does not change spine
densities in the basolateral amygdala (BLA). (A) Representative image
of a Golgi-stained principal neuron in the BLA; scale bar: 20μm.The inset
is a high magniﬁcation image of the primary dendrite segment marked by
the red box; scale bar: 5μm. (B) Schematic of a BLA principal neuron;
spines are counted along the ﬁrst 80μm stretch of the primary dendrite.
(C) Representative dendritic segments from BLA spiny principal neurons
of saline and ﬂuoxetine injected animals; scale bar: 5μm. (D)Total number
of spines in the 80μm stretch of the dendrite analyzed. (E)The distribution
of spine density over 10μm segments along the 80μm stretch of the
dendrite analyzed. Saline: N =5, Fluoxetine: N =5. Error bars represent
SEM.
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FIGURE 3 | In vivo acute fluoxetine administration increases the
intrinsic excitability of LA principal neurons measured ex vivo.
(A) Schematic representation of the experimental protocol. MaleWistar rats
were injected with ﬂuoxetine (10mg/kg, i.p.) or saline and sacriﬁced 60min
later. Whole-cell patch clamp recordings were then carried out on excitatory
principal neurons in the LA in the current-clamp mode. (B) Representative
spike trains evoked by a 350-pA somatic current injection. (C) Comparison
of the average f–I curves (Instantaneous ﬁring frequency versus current;
Saline: n=11 neurons, Fluoxetine: n=14 neurons). The instantaneous ﬁring
frequency was calculated for a series of somatic current injections from the
average inter-spike interval for each current. Error bars represent SEM;
*p<0.01.
for 350 pA current injection, Saline: 18.8± 0.7Hz, n = 11 neu-
rons; Fluoxetine: 21.2± 0.6Hz, n = 14 neurons; p< 0.5). Thus,
acute in vivo treatment with ﬂuoxetine enhances spike ﬁring of
LA principal neurons at the same time point after acute ﬂuoxe-
tine administration when animals exhibited increased anxiety-like
behavior.
IN VITRO APPLICATION OF FLUOXETINE INCREASES EXCITABILITY OF
AMYGDALA NEURONS IN BRAIN SLICES
Our results from the ex vivo slice recordings raise the possibility
that acute administration of ﬂuoxetine enhances spike ﬁrings in
LA neurons. To examine this possibilitymore directly we extended
our analysis by examining if in vitro bath application of ﬂuoxetine
in brain slices enhances action potential ﬁring in LA neurons. We
used the same experimental design involving whole-cell current-
clamp recordings in LA excitatory principal neurons that showed
spike frequency accommodation in response to depolarizing cur-
rent injections. The spiking response of each cell in response to a
series of somatic depolarizing current injection steps was recorded
before and30min after a 15-minbath applicationof 50μMﬂuoxe-
tine followed by a 30-minwashout with normal aCSF (Figure 4A).
We then compared the average ﬁring frequency versus current (f–
I) plots before the ﬂuoxetinewash-in and at the end of thewashout
period (Figure 4C). Fluoxetine application signiﬁcantly enhanced
the ﬁring rate of LA neurons [F (1, 7) = 10.73, p< 0.05]. There
was also a signiﬁcant effect of current injection on ﬁring rates
[F (4, 28) = 280.55, p< 0.001]. Further, the interaction between
treatment and current injection was signiﬁcant [F (4, 28) = 10.17,
p< 0.001]. This was manifested as a lowering of the amplitude of
the depolarizing current steps required to attain saturating ﬁring
frequencies in the presence of ﬂuoxetine. Pairwise comparisons
also show that bath application of ﬂuoxetine increases pyramidal
cell excitability (Figures 4B,C; for 150 pA current injection, Pre-
ﬂuoxetine: 12± 0.5Hz, Post ﬂuoxetine 16± 2Hz, n = 8 neurons,
p< 0.01).
FIGURE 4 | Acute fluoxetine application increased excitability of LA
neurons. (A) Schematic representation of the experimental protocol.
Excitability was measured using a range of supra-threshold current
injections both during baseline and 30min after the end of ﬂuoxetine
(50μM, 15min) application. (B) Action potential ﬁring induced by
depolarizing current injections from a representative neuron pre (left ) and
post (right ) ﬂuoxetine treatment. (C) Averaged ﬁring frequency versus
current relationship (f–I curve) shows the increase in excitability after
ﬂuoxetine application (n=8 neurons) across a range of current injections.
Error bars represent SEM; *p<0.05, **p<0.01.
In order to follow the time-course of this increase in spik-
ing output caused by ﬂuoxetine application, we next followed
the spiking activity of individual cells in response to a 500-ms
current step of ﬁxed magnitude during the pre-ﬂuoxetine base-
line, ﬂuoxetine application, and washout period. The current step
was adjusted to elicit an average of four to ﬁve action potentials.
After obtaining a steady baseline (Figure 5A, left, Baseline), bath
application of ﬂuoxetine (50μM, 15min) resulted in an increase
in action potential ﬁring (Figure 5A, middle, Fluoxetine). Mean
values of ﬁring frequency averaged over 5min at the end of
ﬂuoxetine application increased signiﬁcantly when compared to
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FIGURE 5 | Fluoxetine application led to a correlated increase in both
spike frequency and input resistance in LA neurons. (A)Top,
Representative traces of action potentials elicited by supra-threshold current
injections from an LA neuron during baseline, at the end of ﬂuoxetine
application and after washout. Bottom, time-course plot showing the
persistent increase in spike frequency found only in ﬂuoxetine-treated
neurons and not in aCSF-treated control neurons. (B) Individual
(ﬂuoxetine – black circles, saline – white circles) and averaged (individual
values averaged over 5min, gray squares) values of spike frequency for
ﬂuoxetine (left, n=9 neurons) and aCSF (right, n=8 neurons) treated
control neurons. (C)Top, the voltage response to hyperpolarizing current
injections used to measure the input resistance is shown for a
representative neuron before, during, and after ﬂuoxetine application.
Bottom, time-course of input resistance averaged (per minute) and
normalized (%) to the baseline for ﬂuoxetine and aCSF-treated control
neurons. (D) Correlation plot indicating that the rise in spike frequency in the
majority of ﬂuoxetine-treated neurons was signiﬁcantly correlated with a
corresponding increase in input resistance. The dotted and gray lines
indicate the linear-ﬁt and 95% conﬁdence bands respectively. Error bars
represent SEM; **p<0.01, ***p<0.001.
pre-drug baseline (Figure 5B; Baseline: 9.2± 0.2Hz, Fluoxetine:
11± 0.2Hz, n = 9 neurons, p< 0.01). This increase in ﬁring rate
observed after the end of ﬂuoxetine application was persistent as is
evident from the time-course plot (Figure 5A). The increase in ﬁr-
ing rate remained signiﬁcantly higher than pre-drug baseline even
after the drug was washed out for 30min (Figure 5B, Baseline:
9.2± 0.2Hz, Washout: 12± 0.3Hz, n = 9 neurons, p< 0.001). In
control experiments, treatment with aCSF alone did not induce
any signiﬁcant changes in spiking (Figures 5A,B, open circles).
FLUOXETINE INDUCED INCREASE IN SPIKING IS ACCOMPANIED BY AN
INCREASE IN INPUT RESISTANCE
In addition to recording the spiking response of cells, we also
measured the input resistance for all the cells by measuring their
response to a brief hyperpolarizing current step preceding each
depolarizing current step. Bath application of ﬂuoxetine (50μM,
15min) caused amarked increase (10%) in input resistance which
was signiﬁcantly different from the baseline (242± 13MΩ) both
immediately after ﬂuoxetine application (Figure 5C, Fluoxetine:
264± 14MΩ, n = 9 neurons, p< 0.001) and at the end of the
washout period (Figure 5C, Washout: 267± 14MΩ, n = 9 neu-
rons, p< 0.01). In contrast, control cells treated with aCSF alone,
showed no signiﬁcant change in input resistance (Figure 5C,
Open circles). Importantly, the increase in input resistance mea-
sured at the end of the washout period for each ﬂuoxetine-treated
cell was positively correlated with the increase in ﬁring rate
(Figure 5D; R = 0.75, p< 0.05). This suggests that the increase
in input resistance may contribute to the enhanced spiking output
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of LA neurons induced by ﬂuoxetine application, thereby provid-
ing a possible mechanism underlying the ﬁring changes observed
in vitro.
DISCUSSION
Despite growing evidence pointing to a pivotal role for the amyg-
dala in the debilitating emotional symptoms of depression and
anxiety, few studies have addressed the role of cells and circuits
in the amygdala in mediating the behavioral effects of antidepres-
sants. While studies on the hippocampus and cortex have helped
elucidate some of the cellular andmolecularmechanisms thatmay
underlie the cognitive deﬁcits observed in affective disorders, rel-
atively little is known about the cellular basis of the emotional
and mood related symptoms. In this study, we have attempted
to address this gap in knowledge by investigating if changes in
morphological and physiological properties of BLA neurons may
provide a cellular correlate for the acute effects of SSRI treatment.
Consistent with previous studies, we ﬁnd that a single injection of
the SSRI ﬂuoxetine leads to a signiﬁcant increase in anxiety-like
behavior in the plus-maze an hour later. Strikingly, this increase
in anxiety is not paralleled by an increase in the density of den-
dritic spines in the ﬁrst 80μm of the primary dendrites of BLA
principal neurons. Previous studies have reported that an increase
in the density of spines, on the same class of dendrites in the
same type of BLA neurons, may in itself be adequate to increase
behavioral anxiety in rodents (Mitra et al., 2005; Govindarajan
et al., 2006). However, our results show that anxiety-like behavior
can be enhanced even in the absence of such modiﬁcations in the
structural connectivity of BLA neurons. Although we could not
detect any stable changes in spine density 1 h after SSRI adminis-
tration, this does not rule out the possibility that SSRI treatment
affects spine dynamics that only result in stable changes in spine
number over longer periods of time or after longer durations of
treatment. Indeed, earlier observations on enhanced anxiety-like
behavior being correlated with BLA spinogenesis were manifested
on a longer time-scale. For example, a robust increase in BLA spine
density was observed after 10 days of chronic stress. Even when a
single 2-h episode of acute stress was able to elicit spinogenesis in
theBLA, the effectwasmanifested 10 days,but not 1 day,after acute
stress (Mitra et al., 2005). Further, our morphological analysis was
restricted to the quantiﬁcation of a speciﬁc parameter, i.e., spine
density in the ﬁrst 80-μm segment of primary apical dendrites of
BLA principal neurons, and does not rule out the possibility that
spine density changes may have occurred in other dendritic com-
partments (e.g., in higher-order branches or in basal dendrites)
or changes in other morphological characteristics such as spine
morphology (size or shape of spines) or dendritic morphology of
BLAprincipal neurons. Future studies would need to address these
possibilities.
The absence of an obvious spine density change led us to
shift our attention to physiological changes in amygdala neurons.
Interestingly, we found that the acute anxiogenic effect of ﬂuoxe-
tine treatment was accompanied by an increase in the excitability
of principal neurons in amygdala slices. Whole-cell recordings
in amygdala slices prepared 1 h after in vivo ﬂuoxetine admin-
istration, as well as in vitro ﬂuoxetine application directly onto
amygdala slices, enhanced action potential ﬁring of LA principal
neurons. Moreover, this increase in excitability of LA cells in
response to ﬂuoxetine applicationwas accompanied by an increase
in the input resistance of these neurons. Importantly, the change
in input resistance exhibits a signiﬁcant positive correlation with
the increase in ﬁring frequency in individual cells, suggesting that
this increase in input resistance is likely to contribute to enhanced
neuronal excitability triggered by ﬂuoxetine.
Many lines of evidence suggest that the enhanced serotonin
availability due to SSRIsmaymediate the increase in BLA excitabil-
ity due to acute ﬂuoxetine treatment. Firstly, in addition to ﬂuox-
etine, the anxiogenic effects of acute SSRI treatment have also
been demonstrated using other SSRIs such as citalopram, paroxe-
tine, sertraline etc. (Griebel et al., 1994; Sanchez and Meier, 1997;
Dekeyne et al., 2000; Kurt et al., 2000; Bagdy et al., 2001; Koks
et al., 2001; Burghardt et al., 2004). Although various SSRIs are
known to differ in their speciﬁcities and binding afﬁnities, all of
them bind to the serotonin transporter with maximum afﬁnity
supporting a role for some serotonin based mechanism in the
observed behavioral effects. Secondly, acute SSRI administration
has been shown to increase extracellular serotonin (Bosker et al.,
2001), and glutamate levels in the amygdala (Reznikov et al., 2007).
Many studies have previously shown that serotonin is capable of
modulating excitatory and inhibitory currents in the amygdala
(Stutzmann et al., 1998; Stutzmann and Ledoux, 1999; Rainnie,
1999) and hence can tip the balance of excitation–inhibition in
favor of increased excitability of BLA neurons. Finally, numer-
ous serotonin receptor subtypes have also been implicated in the
modulation of anxiety-like behavior and a growing body of data
suggests that anxiety induced by serotonin via the 5HT2c receptor
may underlie the acute effects of SSRIs (Dekeyne et al., 2000; Salch-
ner and Singewald, 2006). Thus, many lines of evidence suggest a
serotonin dependent mechanism for the acute effects of SSRIs and
future studies will be needed to further explore a speciﬁc role for
serotonin in the BLA neuronal excitability changes reported here.
On the other hand, anxiety can be induced by a wide range
of pharmacological agents that affect glutamatergic receptors,
inhibitory GABA receptors, and neuromodulatory systems such as
serotonin,norepinephrine, and various neuropeptides. Thus, SSRI
induced anxiety could be brought about by a range of different
mechanisms. Fluoxetine, in addition to increasing serotonin lev-
els, also increases the extracellular levels of other catecholamines
such as norepinephrine and dopamine. The anxiogenic effects of
ﬂuoxetinemay thus bemechanistically similar to other anxiogenic
agents impinging on these neurotransmitter systems (Singewald
et al., 2003). Further, although originally identiﬁed as a selective
serotonin reuptake inhibitor, numerous studies have shown that
ﬂuoxetine can bind to a wide range of other targets at physio-
logically relevant concentrations (Bianchi, 2008). These alternate
binding targets of ﬂuoxetine include certain classes of potas-
sium channels whose activation could lead to the increase in
input resistance in ﬂuoxetine-treated cells (Choi et al., 1999, 2001,
2004; Hahn et al., 1999; Kobayashi et al., 2004; Kennard et al.,
2005; Norman et al., 2005). These mechanisms await further
investigation.
A number of studies have previously suggested a relation-
ship between increased amygdala activity and enhanced fear and
anxiety-like behavior (Rainnie et al., 2004; Manzanares et al.,
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2005; Duvarci and Pare, 2007; Karst et al., 2010). How may the
increase in BLA neuronal excitability observed in our study lead
to heightened fear and anxiety caused by acute ﬂuoxetine treat-
ment? First, such increase in excitability could contribute to a
non-speciﬁc increase in spontaneous activity. This, in turn, would
lead to generalized, cue non-speciﬁc fear that is manifested as
enhanced anxiety. Second, fear conditioning has been shown to
induce increases in conditional stimulus (CS)-evoked spike ﬁr-
ing in LA neurons (Quirk et al., 1995; Collins and Pare, 2000;
Maren, 2000; Maren and Quirk, 2004). Thus, increase in excitabil-
ity in these LAneurons followingﬂuoxetine treatmentwouldmake
themmore susceptible to greater CS-evoked ﬁring compared to LA
neurons in fear-conditioned animals that have not received ﬂuox-
etine injection, and this too would be manifested as a facilitation
of auditory fear conditioning as reported earlier (Burghardt et al.,
2004, 2007).
Our ﬁndings from this study may also provide a useful exper-
imental framework for investigating another interesting aspect of
the effects of SSRI treatment on anxiety and fear memory forma-
tion. Clinical reports indicate that while anxiety is often increased
during early stages of SSRI treatment, it is reduced after several
weeks of treatment. In other words, acute versus chronic treatment
with the same SSRI can elicit opposite effects on anxiety and earlier
studies have captured this dichotomy in rodentmodels of auditory
fear conditioning (Burghardt et al., 2004). Thus, future studies will
be needed to examine if more prolonged SSRI treatment leads to
differential effects on the same physiological and morphological
measures used in the present study. It is also important to note that
the amygdala is a heterogeneous collection of numerous nuclei and
sub-nuclei, and our present analysis has focused only on the input
interface of the amygdala – the lateral and basolateral divisions.
Although the BLA is most well studied for its role in fear memory
acquisition and expression,more recent studies suggest important
roles for output nuclei of the amygdala (Pare et al., 2004; Ehrlich
et al., 2009; Amano et al., 2010) as well as extended amygdala
structures such as the bed nucleus of stria terminalis (BNST) in
the regulation of fear and anxiety (Grillon, 2008; Hammack et al.,
2009; Davis et al., 2010). The cellular effects of SSRI treatment
in these regions may differ considerably to those observed in the
BLA. For example, pharmacologically diverse anxiogenic agents
induce Fos expression in the CeA (Singewald et al., 2003). Inter-
estingly, repeated restraint stress leads to an up-regulation of the
extracellularmatrix protease tissue plasminogen activator (tPA) in
the medial (MeA) and central nucleus of the amygdala (CeA), but
not BLA. Further, the same repeated stress that elicits enhanced
anxiety and spinogenesis in the BLA actually lowers spine density
in the MeA. Importantly, stress-induced spine loss in the MeA is
tPA-dependent, but stress-induced spinogenesis in the BLA is not
(Bennur et al., 2007; Roozendaal et al., 2009). It will, therefore,
be important to assess the potential contributions of these out-
put nuclei of the amygdala to the anxiogenic effects of acute SSRI
treatment. Together, amore rigorous analysis of the impact of both
acute and chronic treatment with SSRIs on cells and microcircuits
of the amygdala will be critically important for improving our
understanding of both the beneﬁcial, as well as the undesirable
side-effects, of antidepressant treatments.
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